Gene inactivation of the cyclin‑dependent kinase inhibitors p16INK4a, p15INK4b and p21WAF is frequently mediated by promoter gene methylation, whereas histone deacetylases (HDACs) control gene expression through their ability to deacetylate proteins. The effect of suberohydroxamic acid (SBHA) and 5‑Aza‑2'‑deoxycytidine (Decitabine) (DAC) treatments on the transcription of CDKN2A, CDKN2B and CDKN1A genes, and their effects on molecular biological behavior were examined in two myeloma cell lines, RPMI8226 and U266, which differ in p53‑functionality and IL‑6 expression. In both tested myeloma cell lines, a non‑methylated state of the CDKN2B gene promoter region was detected with normal gene expression, and the same level of p15INK4b protein was detected by immunocytochemical staining. Furthermore, in myeloma cells treated with SBHA and DAC alone, the expression of both p15INK4b and p21WAF was significantly upregulated in RPMI8226 cells (p53‑functional, without IL‑6 expression), whereas in the U266 cell line (p53 deleted, expressing IL‑6) only p21WAF expression was significantly increased. Moreover, the analysis revealed that treatment with DAC induced DNMT3B enhancement in U266 cells. In conclusion, in myeloma cells with IL‑6 expression, significantly increased DNMT3B expression indicated the tumorigenic consequences of 5‑Aza‑2'deoxycytidine treatment, which requires careful use in diseases involving epigenetic dysregulation, such as multiple myeloma (MM).

Department of Biology Faculty of Medicine and Dentistry Palacky University Olomouc 777 15 Olomouc Czech Republic

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University Olomouc 777 15 Olomouc Czech Republic

Department of Hemato‑Oncology University Hospital Olomouc 779 00 Olomouc Czech Republic

Department of Histology and Embryology Faculty of Medicine and Dentistry Palacky University Olomouc 777 15 Olomouc Czech Republic

Department of Microbiology Faculty of Medicine and Dentistry Palacky University Olomouc 777 15 Olomouc Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc 779 00 Olomouc Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University 121 08 Prague Czech Republic

Zobrazit více v PubMed

Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049–3058. doi: 10.1182/blood-2014-11-568881. PubMed DOI PMC

Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011;94:334–343. doi: 10.1007/s12185-011-0949-x. PubMed DOI

Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14:2519–2526. doi: 10.1158/1078-0432.CCR-07-2223. PubMed DOI

Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol. 2015;20:413–422. doi: 10.1007/s10147-015-0837-0. PubMed DOI

Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne) 2019;9:788. doi: 10.3389/fendo.2018.00788. PubMed DOI PMC

Choudhury SR, Ashby C, Tytarenko R, Bauer M, Wang Y, Deshpande S, Den J, Schinke C, Zangari M, Thanendrarajan S, et al. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020;13:108. doi: 10.1186/s13045-020-00933-y. PubMed DOI PMC

Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013;190:2966–2975. doi: 10.4049/jimmunol.1202493. PubMed DOI PMC

Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117:553–562. doi: 10.1182/blood-2010-04-279539. PubMed DOI

Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K, De Bruyne E. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget. 2014;5:3115–3129. doi: 10.18632/oncotarget.1821. PubMed DOI PMC

Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6:1718–1727. doi: 10.1158/1535-7163.MCT-07-0010. PubMed DOI

Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269:7–17. doi: 10.1016/j.canlet.2008.03.037. PubMed DOI

Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784. doi: 10.1038/nrd2133. PubMed DOI

Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 1997;89:2500–2506. doi: 10.1182/blood.V89.7.2500. PubMed DOI

Wong IH, Ng MH, Lee JC, Lo KW, Chung YF, Huang DP. Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation. Br J Haematol. 1998;103:168–175. PubMed

Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 2004;3:425–435. doi: 10.1158/1535-7163.425.3.4. PubMed DOI

Gillespie S, Borrow J, Zhang XD, Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis. 2006;11:2251–2265. doi: 10.1007/s10495-006-0283-6. PubMed DOI

Elmallah MIY, Micheau O. Epigenetic regulation of TRAIL signaling: Implication for cancer therapy. Cancers (Basel) 2019;11:850. doi: 10.3390/cancers11060850. PubMed DOI PMC

Chen J, Hong Z, Zhao C, Bi Q, Qiu B. Associations between polymorphisms of the PDLIM4 gene and susceptibility to osteoporotic fracture in an elderly population of Han Chinese. Biosci Rep. 2019;39:BSR20181505. doi: 10.1042/BSR20181505. PubMed DOI PMC

Kadrmas JL, Beckerle MC. The LIM domain: From the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 2004;5:920–931. doi: 10.1038/nrm1499. PubMed DOI

Ono R, Kaisho T, Tanaka T. PDLIM1 inhibits NF-κB-mediated inflammatory signaling by sequestering the p65 subunit of NF-κB in the cytoplasm. Sci Rep. 2015;5:18327. doi: 10.1038/srep18327. PubMed DOI PMC

Kravchenko DS, Ivanova AE, Podshivalova ES, Chumakov SP. PDLIM4/RIL-mediated regulation of Src and malignant properties of breast cancer cells. Oncotarget. 2020;11:22–30. doi: 10.18632/oncotarget.27410. PubMed DOI PMC

Li Y, Qian J, Lin J, Qian W, Yang J, Chai HY, Wang CZ, Deng ZQ, Yao DM, Chen Q, Ma JC. Reduced expression of PDLIM4 gene correlates with good prognosis in acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:1111–1115. PubMed

Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res. 2006;12:1128–1136. doi: 10.1158/1078-0432.CCR-05-2072. PubMed DOI

Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 2007;67:1997–2005. doi: 10.1158/0008-5472.CAN-06-3093. PubMed DOI

Fernando RC, de Carvalho F, Mazzotti DR, Evangelista AF, Braga WMT, de Lourdes Chauffaille M, Leme AFP, Colleoni GWB. Multiple myeloma cell lines and primary tumors proteoma: Protein biosynthesis and immune system as potential therapeutic targets. Genes Cancer. 2015;6:462–471. doi: 10.18632/genesandcancer.88. PubMed DOI PMC

Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973–1976. doi: 10.3324/haematol.2010.023697. PubMed DOI PMC

Wei B, Yang S, Zhang B, Feng Y. Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: A meta-analysis. Onco Targets Ther. 2016;9:4015–4022. doi: 10.2147/OTT.S102733. PubMed DOI PMC

Li J, Bi L, Lin Y, Lu Z, Hou G. Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma. Drug Des Devel Ther. 2014;8:2129–2136. doi: 10.2147/DDDT.S71088. PubMed DOI PMC

Nguen DH, Zhou T, Shu J, Mao JH. Quantifying chromogen intensity in immunohistochemistry via reciprocal intensity. Cancer InCytes. 2013;2:1–4.

Ingersoll SB, Thoni ND, Ahmed F, Monahan KA, Caballero L, Batista A, Ahmad S, Edwards JR. Role of the IL-6 pathway to multiple myeloma cell growth and its implications in target gene hypermethylation. Blood. 2007;110:4769. doi: 10.1182/blood.V110.11.4769.4769. DOI

Ingersoll SB, Ahmad S, Thoni ND, Ahmed FH, Monahan KA, Edwards JR. Targeting the IL-6 pathway in multiple myeloma and its implications in cancer-associated gene hypermethylation. Med Chem. 2011;7:473–479. doi: 10.2174/157340611796799159. PubMed DOI

Hodge DR, Li D, Qi SM, Farrar WL. IL-6 induces expression of the Fli-1 proto-oncogene via STAT3. Biochem Biophys Res Commun. 2002;292:287–291. doi: 10.1006/bbrc.2002.6652. PubMed DOI

Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, Munroe DJ, Farrar WL. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005;65:4673–4682. doi: 10.1158/0008-5472.CAN-04-3589. PubMed DOI

Oka M, Meacham AM, Hamazaki T, Rodić N, Chang LJ, Terada N. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2′-deoxycytidine. Oncogene. 2005;24:3091–3099. doi: 10.1038/sj.onc.1208540. PubMed DOI

Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR, Fan LP. Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells. Oncol Rep. 2010;24:335–343. PubMed

Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, et al. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. J Hematol Oncol. 2018;11:137. doi: 10.1186/s13045-018-0679-0. PubMed DOI PMC

Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96:574–582. doi: 10.3324/haematol.2010.033456. PubMed DOI PMC

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100–113. doi: 10.1038/nrclinonc.2016.122. PubMed DOI

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, et al. The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clin Cancer Res. 2016;22:5783–5794. doi: 10.1158/1078-0432.CCR-15-1790. PubMed DOI PMC

Caprio C, Sacco A, Giustini V, Roccaro AM. Epigenetic aberrations in multiple myeloma. Cancers (Basel) 2020;12:2996. doi: 10.3390/cancers12102996. PubMed DOI PMC

Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654–3663. doi: 10.1182/blood.V83.12.3654.bloodjournal83123654. PubMed DOI

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, et al. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer. 2005;42:117–127. doi: 10.1002/gcc.20123. PubMed DOI

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745–1757. doi: 10.1182/blood.V99.5.1745. PubMed DOI

Claus R, Lübbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003;22:6489–6496. doi: 10.1038/sj.onc.1206814. PubMed DOI

Nan X, Cross S, Bird A. Gene silencing by methyl-CpG-binding proteins. Novartis Found Symp. 1998;214:6–21. 46–50. PubMed

Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–475. doi: 10.1016/j.cytogfr.2004.06.004. PubMed DOI

Burger R, Günther A, Klausz K, Staudinger M, Peipp M, Penas EM, Rose-John S, Wijdenes J, Gramatzki M. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017;102:381–390. doi: 10.3324/haematol.2016.145060. PubMed DOI PMC

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20. doi: 10.1042/bj20030407. PubMed DOI PMC

Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C, Rédini F, Heymann D, Blanchard F. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res. 2004;19:1850–1861. doi: 10.1359/JBMR.040817. PubMed DOI

Blanchard F, Duplomb L, Baud'huin M, Brounais B. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev. 2009;20:19–28. doi: 10.1016/j.cytogfr.2008.11.004. PubMed DOI

Bellido T, O'Brien CA, Roberson PK, Manolagas SC. Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem. 1998;273:21137–21144. doi: 10.1074/jbc.273.33.21137. PubMed DOI

Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): Modulation by growth factors and cytokines. J Bone Miner Res. 1998;13:793–802. doi: 10.1359/jbmr.1998.13.5.793. PubMed DOI

Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5:e9001. doi: 10.1371/journal.pone.0009001. PubMed DOI PMC

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers (Basel) 2013;5:430–461. doi: 10.3390/cancers5020430. PubMed DOI PMC

Schmelz K, Sattler N, Wagner M, Lübbert M, Dörken B, Tamm I. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia. 2005;19:103–111. doi: 10.1038/sj.leu.2403552. PubMed DOI

Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: Signalling towards p21cip1/waf1. Int J Biochem Cell Biol. 2007;39:1367–1374. doi: 10.1016/j.biocel.2007.03.001. PubMed DOI

Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, Seiser C. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol. 2003;23:2669–2679. doi: 10.1128/MCB.23.8.2669-2679.2003. PubMed DOI PMC

Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97:10014–10019. doi: 10.1073/pnas.180316197. PubMed DOI PMC

Li J, Zheng X, Gao M, Zhao J, Li Y, Meng X, Qian B, Li J. Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in anaplastic thyroid carcinoma through p53. Oncol Rep. 2017;37:458–464. doi: 10.3892/or.2016.5281. PubMed DOI

Wang X, Zhu YB, Cui HP, Yu TT. Aberrant promoter methylation of p15 (INK4b) and p16 (INK4a) genes may contribute to the pathogenesis of multiple myeloma: A meta-analysis. Tumour Biol. 2014;35:9035–9043. doi: 10.1007/s13277-014-2054-2. PubMed DOI

Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol. 2010;89:191–199. doi: 10.1007/s00277-009-0818-3. PubMed DOI

Luzna P, Flodrova P, Janovska L, Zapletalova J, Minarik J, Kolar Z, Trtkova KS. Different gene methylation status of the CDKN2B and/or PDLIM4 as the result of comparative analysis to the global DNA methylation in unsorted cell population of multiple myeloma patients. Ann Hematol Oncol. 2019;6:1257.

Yuregir OO, Yurtcu E, Kizilkilic E, Kocer NE, Ozdogu H, Sahin FI. Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J Lab Hematol. 2010;32:142–149. doi: 10.1111/j.1751-553X.2009.01146.x. PubMed DOI

Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, et al. Tumor suppressor p16 methylation in multiple myeloma: Biological and clinical implications. Blood. 2007;109:1228–1232. doi: 10.1182/blood-2006-05-024661. PubMed DOI